LONDON (ShareCast) - (Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.
Scancell signed the collaboration and non-exclusive research agreement with the unnamed company to assess its pipeline of monoclonal antibodies, targeting tumour-associated glycans that had been enhanced with its new proprietary AvidiMab technology.

Under the terms of the collaboration and research agreement, Scancell and its partner will evaluate the potential of anti-tumour-associated glycans monoclonal antibodies, enhanced with AvidiMab in various formats - including, antibody-drug conjugates, bispecific antibodies, as well as stand-alone antibody products.

The AIM-listed group has filed a patent application that seeks broad protection for its AvidiMab technology.

Chief executive Dr Cliff Holloway said: "We are pleased to be able to report significant progress on our monoclonal antibody pipeline, having only licensed the technology into the company just over a year ago from the University of Nottingham.

"Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential."

As of 0900 BST, Scancell shares had climbed 5.32% to 7.42p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE